31 related articles for article (PubMed ID: 34376567)
1. Clinical use of the Onclarity test with extended HPV genotyping and phenotyping in patients with suspected squamous intraepithelial lesions.
Pruski D; Millert-Kalinska S; Klemenska P; Jach R; Przybylski M
Ginekol Pol; 2024; 95(5):328-334. PubMed ID: 38099664
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of YD MolecuTech Real HPV Assay in Comparison with Roche Cobas HPV Assay and BD Onclarity HPV Assay for Detection of HPV Infection.
Park CH; Kim CW; Lee HW; Kwon MJ
Ann Clin Lab Sci; 2024 Mar; 54(2):239-245. PubMed ID: 38802145
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Novaplex II HPV28 Detection Assay for HPV Typing in Formalin-Fixed, Paraffin-Embedded Tissues.
Thapa HR; Unger ER; Querec TD
J Mol Diagn; 2023 Apr; 25(4):211-216. PubMed ID: 36693473
[TBL] [Abstract][Full Text] [Related]
4. High rate of high-risk human papillomavirus among benign and breast cancer patients in Ethiopia.
Belachew EB; Desta AF; Mulu A; Deneke DB; Tefera DA; Alemu A; Anberber E; Beshah D; Girma S; Sewasew DT; Tessema TS; Howe R
PLoS One; 2024; 19(3):e0298583. PubMed ID: 38507429
[TBL] [Abstract][Full Text] [Related]
5. Detection and Genotyping of Human Papillomavirus DNA in Formalin-Fixed Paraffin-Embedded Specimens with the HPV Direct Flow CHIP System.
Herraez-Hernandez E; Preda O; Alonso S; Pardo RS; Olmo A
Open Virol J; 2013; 7():91-5. PubMed ID: 24222806
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study.
Mena M; Lloveras B; Tous S; Bogers J; Maffini F; Gangane N; Kumar RV; Somanathan T; Lucas E; Anantharaman D; Gheit T; Castellsagué X; Pawlita M; de Sanjosé S; Alemany L; Tommasino M;
PLoS One; 2017; 12(10):e0184520. PubMed ID: 29036167
[TBL] [Abstract][Full Text] [Related]
7. Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
Hortlund M; Mühr LSA; Lagheden C; Hjerpe A; Dillner J
Int J Cancer; 2021 Dec; 149(12):2083-2090. PubMed ID: 34418082
[TBL] [Abstract][Full Text] [Related]
8. A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada.
Weston G; Dombrowski C; Steben M; Popadiuk C; Bentley J; Adams EJ
Prev Med Rep; 2021 Sep; 23():101448. PubMed ID: 34381664
[TBL] [Abstract][Full Text] [Related]
9. Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology.
Chen SJ; Rai CI; Wang SC; Chen YC
Diagnostics (Basel); 2023 Jul; 13(13):. PubMed ID: 37443646
[TBL] [Abstract][Full Text] [Related]
10. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
[TBL] [Abstract][Full Text] [Related]
11. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
[TBL] [Abstract][Full Text] [Related]
12. High-risk human papillomavirus (HPV) detection in formalin-fixed paraffin-embedded cervical tissues: performances of Aptima HPV assay and Beckton Dickinson (BD) Onclarity assay.
Kir G; Gunel H; Olgun ZC; McCluggage WG
J Clin Pathol; 2023 Jan; 76(1):40-46. PubMed ID: 34376567
[TBL] [Abstract][Full Text] [Related]
13. Onclarity Performance in Human Papillomavirus DNA Detection in Formalin-Fixed Paraffin-Embedded Cervical Samples.
Bottari F; Passerini R; Renne G; Guerrieri ME; Sandri MT; Li A; Orlandini A; Iacobone AD
J Low Genit Tract Dis; 2021 Jul; 25(3):216-220. PubMed ID: 34176913
[TBL] [Abstract][Full Text] [Related]
14. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
15. Comparison of the Clinical Performance of Aptima HPV Assay and the Cobas 4800 Platform in Women with Normal Cytology and Positive High-Risk HPV.
Kir G; Dokmeci Guney D; Seneldir H
Acta Cytol; 2023; 67(4):395-402. PubMed ID: 36977394
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
